To evaluate the hemodynamic effects of hydralazine in four patients with primary pulmonary hypertension, we catheterized the right side of the heart before and 48 hours after starting therapy with oral hydralazine, 50 mg every six hours. Data were obtained at rest in four patients and also during exercise in three. After hydralazine, total pulmonary resistance at rest fell from 17.5 to 7.7 U, and pulmonary arteriolar resistance from 15.6 to 7.1 U; cardiac output increased from 3.8 to 7.1 liters per minute, and the arteriovenous oxygen difference narrowed from 7.8 to 5.4 ml per deciliter. Mean pulmonary and systemic arterial pressures were unchanged. Hydralazine also caused total pulmonary resistance during exercise to fall from 15.7 to 10.2 U, and cardiac output to rise from 4.7 to 7.0 liters per minute. Treatment was continued, and on repeat catheterizations three to six months later the hemodynamic effects persisted. These data suggest that hydralazine can reduce pulmonary resistance in some patients with idiopathic pulmonary hypertension.
This article has been cited by other articles:
Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M.
(2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis
2: 249-265
[Abstract]
Nagaya, N., Kyotani, S., Uematsu, M., Ueno, K., Oya, H., Nakanishi, N., Shirai, M., Mori, H., Miyatake, K., Kangawa, K.
(2004). Effects of Adrenomedullin Inhalation on Hemodynamics and Exercise Capacity in Patients With Idiopathic Pulmonary Arterial Hypertension. Circulation
109: 351-356
[Abstract][Full Text]
Nagaya, N., Uematsu, M., Okano, Y., Satoh, T., Kyotani, S., Sakamaki, F., Nakanishi, N., Miyatake, K., Kunieda, T.
(1999). Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol
34: 1188-1192
[Abstract][Full Text]
Mok, M Y, Tse, H F, Lau, C S
(1999). Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Lupus
8: 328-331
[Abstract]
Adrie, C., Ichinose, F., Holzmann, A., Keefer, L., Hurford, W. E., Zapol, W. M.
(1998). Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension. J. Appl. Physiol.
84: 435-441
[Abstract][Full Text]
Chen, E. P., Bittner, H. B., Craig, D. M., Davis, R. D. Jr, Van Trigt, P. III
(1997). Pulmonary Hemodynamics and Blood Flow Characteristics in Chronic Pulmonary Hypertension. Ann. Thorac. Surg.
63: 806-813
[Abstract][Full Text]
Alpert, M. A., Concannon, M. D., Mukerji, B., Mukerji, V.
(1994). Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension. ANGIOLOGY
45: 667-676
[Abstract]
Hammond, T. G., Mosesson, M. W.
(1989). Fatal Small-Bowel Necrosis and Pulmonary Hypertension in Sickle Cell Disease. Arch Intern Med
149: 447-448
[Abstract]
PACKER, M.
(1985). Vasodilator Therapy for Primary Pulmonary Hypertension: Limitations and Hazards. ANN INTERN MED
103: 258-270
[Abstract]
RUBIN, L. J., NICOD, P., HILLIS, L. D., FIRTH, B. G.
(1983). Treatment of Primary Pulmonary Hypertension with Nifedipine: A Hemodynamic and Scintigraphic Evaluation. ANN INTERN MED
99: 433-438
[Abstract]
PEARL, R. G., ROSENTHAL, M. H., SCHROEDER, J. S., ASHTON, J. P. A.
(1983). Acute Hemodynamic Effects of Nitroglycerin in Pulmonary Hypertension. ANN INTERN MED
99: 9-13
[Abstract]
HERMILLER, J. B., BAMBACH, D., THOMPSON, M. J., HUSS, P., FONTANA, M. E., MAGORIEN, R. D., UNVERFERTH, D. V., LEIER, C. V.
(1982). Vasodilators and Prostaglandin Inhibitors in Primary Pulmonary Hypertension. ANN INTERN MED
97: 480-489
[Abstract]
Kronzon, I., Cohen, M., Winer, H. E.
(1982). Adverse Effect of Hydralazine in Patients With Primary Pulmonary Hypertension. JAMA
247: 3112-3114
[Abstract]
Bates, E. R., Crevey, B. J., Sprague, F. R., Pitt, B.
(1981). Oral Hydralazine Therapy for Acute Pulmonary Embolism and Low Output State. Arch Intern Med
141: 1537-1538
[Abstract]
FISHMAN, A. P.
(1981). Primary Pulmonary Hypertension: More Light or More Tunnel?. ANN INTERN MED
94: 815-817
[Abstract]
